{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:19Z","timestamp":1791497599503,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07766-2","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T08:19:53Z","timestamp":1756196393000},"page":"1117-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article"],"prefix":"10.1007","volume":"40","author":[{"given":"Ali","family":"Al-Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Kidess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rasheed","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hazique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-4566","authenticated-orcid":false,"given":"MChadi","family":"Alraies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"7766_CR1","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.2174\/138161206778522029","volume":"12","author":"AJ Thompson","year":"2006","unstructured":"Thompson AJ, Lummis SC. 5-HT3 receptors. Curr Pharm Des. 2006;12:3615\u201330.","journal-title":"Curr Pharm Des"},{"key":"7766_CR2","unstructured":"Griddine A, Bush JS. Ondansetron. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2025. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499839\/.\u00a0Accessed 20 Aug 2025"},{"key":"7766_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/AOG.0000000000001375","volume":"127","author":"LL Siminerio","year":"2016","unstructured":"Siminerio LL, Bodnar LM, Venkataramanan R, Caritis SN. Ondansetron use in pregnancy. Obstet Gynecol. 2016;127:873\u20137.","journal-title":"Obstet Gynecol"},{"key":"7766_CR4","doi-asserted-by":"publisher","unstructured":"Miles JR. Important role corrections has played in health care. J Correct Health Care. 2010;16:97.  https:\/\/doi.org\/10.1177\/1078345809360307","DOI":"10.1177\/1078345809360307"},{"key":"7766_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0022-3565(24)38946-3","volume":"295","author":"YA Kuryshev","year":"2000","unstructured":"Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000;295:614\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"7766_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.3455","volume":"23","author":"KY Tay","year":"2014","unstructured":"Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995\u20132009. Pharmacoepidemiol Drug Saf. 2014;23:9\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7766_CR7","unstructured":"GlaxoSmithKline. A randomized, double-blind, four-period crossover study to investigate the effect of intravenous ondansetron, a 5-HT3 antagonist, on cardiac conduction as compared to placebo and moxifloxacin in healthy adult subjects [Internet]. clinicaltrials.gov; 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01449188"},{"key":"7766_CR8","unstructured":"US Food and Drug Administration. FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). FDA [Internet]. 2021. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran.\u00a0Accessed 20 Aug 2025"},{"key":"7766_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013\u201322.","journal-title":"N Engl J Med"},{"key":"7766_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pharmthera.2011.02.003","volume":"130","author":"TK Machu","year":"2011","unstructured":"Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130:338\u201347.","journal-title":"Pharmacol Ther"},{"key":"7766_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","volume":"13","author":"L Brygger","year":"2014","unstructured":"Brygger L, Herrstedt J. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf. 2014;13:1407\u201322.","journal-title":"Expert Opin Drug Saf"},{"key":"7766_CR12","doi-asserted-by":"crossref","unstructured":"Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Medicine. 2015;13:142.","DOI":"10.1186\/s12916-015-0379-3"},{"key":"7766_CR13","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/j.1528-1167.2009.02139.x","volume":"50","author":"NN Singh","year":"2009","unstructured":"Singh NN, Rai A, Selhorst JB, Acharya JN. Ondansetron and seizures. Epilepsia. 2009;50:2663\u20136.","journal-title":"Epilepsia"},{"key":"7766_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","volume":"64","author":"SB Freedman","year":"2014","unstructured":"Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19\u201325.","journal-title":"Ann Emerg Med"},{"key":"7766_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/00043426-200112000-00005","volume":"23","author":"RI Parker","year":"2001","unstructured":"Parker RI, Prakash D, Mahan RA, Giugliano DM, Atlas MP. Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. J Pediatr Hematol Oncol. 2001;23:578\u201381.","journal-title":"J Pediatr Hematol Oncol"},{"key":"7766_CR16","doi-asserted-by":"crossref","unstructured":"Kim YS, Yoon SH, Choi YH, Park CM, Lee W, Goo JM. Nausea and vomiting after exposure to non-ionic contrast media: incidence and risk factors focusing on preparatory fasting. Br J Radiol. 2018;91:20180107.","DOI":"10.1259\/bjr.20180107"},{"key":"7766_CR17","doi-asserted-by":"crossref","unstructured":"Orozco BS, Lee SC, Fuchs RT, Fushianes GD, Cole JB. QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron. Am J Emerg Med. 2023;68:214.e3\u2013214.e6.","DOI":"10.1016\/j.ajem.2023.04.003"},{"key":"7766_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.14503\/THIJ-16-6040","volume":"44","author":"DY Lee","year":"2017","unstructured":"Lee DY, Trinh T, Roy SK. Torsades de pointes after ondansetron infusion in 2 patients. Tex Heart Inst J. 2017;44:366\u20139.","journal-title":"Tex Heart Inst J"},{"key":"7766_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1681\/ASN.0000000000000336","volume":"35","author":"S Ismail","year":"2024","unstructured":"Ismail S, Funk MJ, Flythe JE. Ondansetron and the risk of sudden cardiac death among individuals receiving maintenance hemodialysis. J Am Soc Nephrol. 2024;35:761\u201371.","journal-title":"J Am Soc Nephrol"},{"key":"7766_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2146\/ajhp161070","volume":"75","author":"K Li","year":"2018","unstructured":"Li K, Vo K, Lee BK, Addo N, Coralic Z. Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients. Am J Health Syst Pharm. 2018;75:276\u201382.","journal-title":"Am J Health Syst Pharm"},{"key":"7766_CR21","doi-asserted-by":"crossref","unstructured":"Rezaei Zadeh Rukerd M, Shahrbabaki FR, Movahedi M, Honarmand A, Pourzand P, Mirafzal A. Single intravenous dose ondansetron induces QT prolongation in adult emergency department patients: a prospective observational study. Int J Emerg Med. 2024;17:49.","DOI":"10.1186\/s12245-024-00621-5"},{"key":"7766_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajem.2024.08.011","volume":"85","author":"HY M\u0131s\u0131rl\u0131o\u011flu","year":"2024","unstructured":"M\u0131s\u0131rl\u0131o\u011flu HY, \u0130nce E\u00d6, Akka\u015f M. The effect of intravenous ondansetron on QT interval in the emergency department. Am J Emerg Med. 2024;85:7\u201312.","journal-title":"Am J Emerg Med"},{"key":"7766_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/acem.12836","volume":"23","author":"PM Moffett","year":"2016","unstructured":"Moffett PM, Cartwright L, Grossart EA, O\u2019Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23:102\u20135.","journal-title":"Acad Emerg Med"},{"key":"7766_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/08830738020170111706","volume":"17","author":"RB Khan","year":"2002","unstructured":"Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol. 2002;17:857\u20138.","journal-title":"J Child Neurol"},{"key":"7766_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1517\/14656566.9.4.645","volume":"9","author":"EA Jones","year":"2008","unstructured":"Jones EA. Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opin Pharmacother. 2008;9:645\u201351.","journal-title":"Expert Opin Pharmacother"},{"key":"7766_CR26","unstructured":"Serotonin 5-HT3 Receptor Antagonists. LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548191\/. Accessed 20 Aug 2025"},{"key":"7766_CR27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","volume":"63","author":"K Garsed","year":"2014","unstructured":"Garsed K, Chernova J, Hastings M. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617\u201325.","journal-title":"Gut"},{"key":"7766_CR28","doi-asserted-by":"crossref","unstructured":"Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol. 2018;9:913.","DOI":"10.3389\/fphar.2018.00913"},{"key":"7766_CR29","doi-asserted-by":"crossref","unstructured":"Herrstedt J, Roila F, Warr D. Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2016;2017;25(1):277\u201388.","DOI":"10.1007\/s00520-016-3313-0"},{"key":"7766_CR30","doi-asserted-by":"crossref","unstructured":"Legi A, Rodriguez E, Eckols TK, Mistry C, Robinson P. Substance P antagonism prevents chemotherapy-induced cardiotoxicity. Cancers (Basel). 2021;13:1732.","DOI":"10.3390\/cancers13071732"},{"key":"7766_CR31","doi-asserted-by":"crossref","unstructured":"Jubair S, Li J, Dehlin HM, Manteufel EJ, Goldspink PH, Levick SP, et al. Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT. Am J Physiol Heart Circ Physiol. 2015;309:H676\u2013684.","DOI":"10.1152\/ajpheart.00200.2015"},{"key":"7766_CR32","doi-asserted-by":"crossref","unstructured":"Spinelli T, Moresino C, Baumann S, Timmer W, Schultz A. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. Springerplus. 2014;3:389.","DOI":"10.1186\/2193-1801-3-389"},{"key":"7766_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/1742-6723.14174","volume":"35","author":"L Philpott","year":"2023","unstructured":"Philpott L, Clemensen E, Lau GT. Droperidol versus ondansetron for nausea treatment within the emergency department. Emerg Med Australas. 2023;35:605\u201311.","journal-title":"Emerg Med Australas"},{"key":"7766_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","volume":"102","author":"B Charbit","year":"2005","unstructured":"Charbit B, Albaladejo P, Funck-Brentano C. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094\u2013100.","journal-title":"Anesthesiology"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07766-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:32Z","timestamp":1778649692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7766"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07766-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}